$85.81−2.78 (−3.14%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD
$85.61−0.20 (−0.23%)
After hours: Nov 17, 2026, 7:46 PM ET
CVS Health (CVS) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~8.3%/yr (FY21→FY25), net margin 0.4%, and free cash flow (~$7.8B) tracks net income. Earnings are cash, not paper.
The four lines that matter · FY21–FY25
Revenue ($B)▲7.8%
402.1
FY21→FY25CAGR +8.3%/yr
Net income ($B)▼61.7%
1.8
FY21→FY25CAGR −31.4%/yr
Free cash flow ($B)▲23.4%
7.8
FY21→FY25CAGR −16.1%/yr
Diluted EPS▼62.0%
1.39
buyback-liftedCAGR −30.7%/yr
What the receipts whisper · what a headline number hides
Share count
−4.4%
1.3bn → 1.3bn diluted shares since FY21. Part of EPS growth is the shrinking denominator. Watch net income too.
Capex
$2.8B
steady at 0.7% of revenue (+1.8% YoY).
Returns vs FCF
44%
$3.4B returned vs $7.8B of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($B)
0¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 17.8% → 45.0%. Net margin 0.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 420,614.0 | 402,067.0 | 372,809.0 | 357,776.0 | 322,467.0 | 292,111.0 | ▲7.8% | +8.3% |
Cost of revenue | 234,551.0 | 221,167.0 | 206,287.0 | 217,098.0 | 196,892.0 | 239,991.0 | ▲7.2% | −2.0% |
Gross profit | 186,063.0 | 180,900.0 | 166,522.0 | 140,678.0 | 125,575.0 | 52,120.0 | ▲8.6% | +36.5% |
Selling, general & admin | 44,777.0 | 44,977.0 | 41,706.0 | 39,832.0 | 38,212.0 | 37,021.0 | ▲7.8% | +5.0% |
Total operating expenses | 171,002.0 | 176,240.0 | 158,006.0 | 126,935.0 | 117,621.0 | 38,810.0 | ▲11.5% | +46.0% |
Operating incomefeeds ROC rank | 15,061.0 | 4,660.0 | 8,516.0 | 13,743.0 | 7,954.0 | 13,310.0 | ▼45.3% | −23.1% |
Other income, net | −2,943.0 | −2,524.0 | −2,368.0 | −2,570.0 | −2,118.0 | −2,773.0 | — | — |
Pretax income | 12,118.0 | 2,136.0 | 6,148.0 | 11,173.0 | 5,836.0 | 10,537.0 | ▼65.3% | −32.9% |
Income tax | 1,072.0 | 408.0 | 1,562.0 | 2,805.0 | 1,509.0 | 2,548.0 | ▼73.9% | −36.7% |
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings | 11,037.0 | 1,768.0 | 4,614.0 | 8,344.0 | 4,311.0 | 7,989.0 | ▼61.7% | −31.4% |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | 8.60 | 1.39 | 3.66 | 6.47 | 3.26 | 6.02 | ▼62.0% | −30.7% |
Diluted shares (bn) | 1.29 | 1.27 | 1.26 | 1.29 | 1.32 | 1.33 | ▲0.7% | −1.1% |
| Margins | ||||||||
Gross margin22nd pct in Healthcare | 44.2% | 45.0% | 44.7% | 39.3% | 38.9% | 17.8% | ▲0.3pp | +27.1pp |
Operating margin | 3.6% | 1.2% | 2.3% | 3.8% | 2.5% | 4.6% | ▼1.1pp | −3.4pp |
Net margin47th pct in Healthcare | 2.6% | 0.4% | 1.2% | 2.3% | 1.3% | 2.7% | ▼0.8pp | −2.3pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 14 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-10 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was CVS Health's revenue last fiscal year?
CVS Health reported revenue of $402.1B in fiscal 2025, up 7.8% from fiscal 2024.
What was CVS Health's net income?
CVS Health reported net income of $1.8B in fiscal 2025, a net margin of 0.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

